4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone promoted gastric cancer growth through prostaglandin E receptor (EP2 and EP4) in vivo and in vitro

Cancer Science

Volumn 102, Issue 5, 2011, Pages 926-933

  Shin, Vivian Y ^a   Jin, Hong C ^b   Ng, Enders K O ^a   Cho, Chi H ^c   Leung, Wai K ^c   Sung, Joseph J Y ^c   Chu, Kent Man ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ZHEJIANG UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E4 RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR PROMOTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CARCINOGENS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NITROSAMINES; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954871936     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01885.x     Document Type: Article

References (32)

1. Altekruse SF, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute, 1975. Available from URL.
2. Ladeiras-Lopes R, Pereira AK, Nogueira A et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008; 19: 689-701.
3. Phukan RK, Zomawia E, Narain K, Hazarika NC, Mahanta J. Tobacco use and stomach cancer in Mizoram, India. Cancer Epidemiol Biomarkers Prev 2005; 14: 1892-6.
4. Hishida A, Matsuo K, Goto Y et al. Smoking behavior and risk of Helicobacter pylori infection, gastric atrophy and gastric cancer in Japanese. Asian Pac J Cancer Prev 2010; 11: 313-7.
5. Pfeifer GP, Denissenko MF, Olivier M et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435-51.
6. Browman GP, Wong G, Hodson I et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993; 328: 159-63.
7. Mai SK, Welzel G, Haegele V, Wenz F. The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. Radiat Oncol 2007; 2: 30.
8. Shin VY, Jin HC, Ng EK et al. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 2008; 233: 254-61.
9. Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-73.
10. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-90.
11. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004; 3: 1031-9.
12. Pratesi G, De Cesare M, Carenini N et al. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 2002; 8: 3904-9.
13. Shin VY, Wu WK, Ye YN et al. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis 2005; 25: 2487-95.
14. Liu ES, Ye YN, Shin VY et al. Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis 2003; 24: 1407-13.
15. Tones MA, Sharif NA, Hawthorne JN. Phospholipid turnover during cell-cycle traverse in synchronous Chinese-hamster ovary cells. Mitogeneisis without phosphoinositide breakdown. Biochem J 1988; 249: 51-6.
16. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003; 24: 985-90.
17. Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 2007; 28: 809-15.
18. Shao J, Sheng GG, Mifflin RC, Powell DW, Sheng H. Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res 2006; 66: 846-55.
19. Kawamori T, Uchiya N, Nakatsugi S et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 2001; 22: 2001-4.
20. Tober KL, Thomas-Ahner JM, Maruyama T, Oberyszyn TM. Possible cross-regulation of the E prostanoid receptors. Mol Carcinog 2007; 46: 711-5.
21. Wang X, Klein RD. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol Carcinog 2007; 46: 912-3.
22. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 2008; 283: 3433-44.
23. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
24. Pan MR, Hou MF, Chang HC, Hung WC. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem 2008; 283: 11155-63.
25. Chang SH, Liu CH, Wu MT, Hla T. Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostaglandins Other Lipid Mediat 2005; 76: 48-58.
26. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310: 1504-10.
27. Zhou H, Calaf GM, Hei TK. Malignant transformation of human bronchial epithelial cells with the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Int J Cancer 2003; 106: 821-6.
28. Ashwell S, Zabludoff S. DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008; 14: 4032-7.
29. Ho YS, Chen CH, Wang YJ et al. Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NFkappaB activation and cyclin D1 up-regulation. Toxicol Appl Pharmacol 2005; 205: 133-48.
30. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 1995; 55: 3250-3.
31. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007; 37: 878-86.
32. Dineen SP, Sullivan LA, Beck AW et al. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 2008; 68: 4340-6.